Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Fezolinetant PK in Healthy Females
NCT04641260Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fezolinetant in vasomotor symptoms (2 arms), sponsored by Astellas Pharma. Primary endpoints: Area under the concentration-time Curve from the time of dosing extrapolated to time infinity, Area under the concentration-time curve from the time of dosing to the last measurable concentration and 2 more. Started Nov 2020; status: completed.
02
Drugs
fezolinetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT04641260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04641260.